David Levitz

David Levitz

Auto-generated profile, based on publicly available information

David Levitz

Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY, 10467, United States, +1 (404) 778-1900

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DLDavid Levitz
David Levitz
YSYogen Saunthararajah
Yogen Saunthararajah
KFKateryna Fedorov
Kateryna Fedorov
LSLauren C. Shapiro
Lauren C. Shapiro
IMIoannis Mantzaris
Ioannis Mantzaris
MGMendel Goldfinger
Mendel Goldfinger
Purpose: Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is the new standard of care for elderly patients with acute myeloid leukemia (AML) and is being evaluated in myelodysplastic syndrome (MDS). Current dosing of HMA/VEN relies on leukemia suppression through cytotoxicity which also impacts normal hematopoiesis. A regimen using once-weekly low-dose decitabine (LDDec) has demonstrated activity in myeloid malignancies. To overcome the severe myelosuppression often seen with HMA/VEN, we evaluated a once-weekly dosing regimen of VEN and LDDec in elderly and/or frail patients who were felt less likely to tolerate severe myelosuppression. Patients and Methods: This is a retrospective, single-center analysis of patients with AML, MDS, or chronic myelomonocytic leukemia treated with a once-weekly LDDec/VEN regimen. We also compare this regimen with a cohort treated with standard dosing HMA/VEN. Results: In a retrospective cohort of 39 patients, the overall response rate for patients receiving LDDec/VEN for first-line AML and MDS was 88% and 64%, respectively. In patients with TP53 mutations, the composite complete response rate was 71% and the median overall survival was 10.7 months. When compared with 36 patients receiving standard dose HMA/VEN, the LDDec/VEN patients had a longer time on therapy (175 vs. 78 days; P = 0.014) and a trend toward a higher rate of transfusion independence (47% vs. 26%; P = 0.33). Neutropenic fever occurred in 31% of patients, with a median of one hospitalization at any point during treatment. Conclusions: This preliminary clinical experience, although retrospective, provides proof-of-activity of noncytotoxic DNA methyltransferase 1–targeting by allowing frequent, sustained drug exposure often not possible with standard HMA/VEN regimens.

6 January 2026 in JMIR Cancer
Verified
Journal Article
Open access
LALemchukwu Amaeshi
Lemchukwu Amaeshi
LLLauren Laufer
Lauren Laufer
KFKateryna Fedorov
Kateryna Fedorov
ASAlex Sisto
Alex Sisto
DLDavid Levitz
David Levitz
NSNishi Shah
Nishi Shah
Background: Patients with cancer often face significant financial challenges, known as financial toxicity (FT), which is associated with reduced quality of life. Patients with hematologic malignancies (HMs) are especially vulnerable due to intensive and prolonged treatments, frequent hospital visits, and a high risk of complications. While FT affects many in the general population, it is particularly severe among racial and ethnic minorities, especially those below the poverty line. To our knowledge, no studies have specifically examined FT in this vulnerable group in the United States. Objective: This study aimed to evaluate the severity of FT in patients receiving treatment for HMs in a socioeconomically underserved population, explore sociodemographic factors that may predict the severity of FT, and evaluate the subjective experiences of these patients as they relate to FT. Methods: We conducted a prospective, observational, longitudinal study at the Montefiore Cancer Center’s outpatient department in the Bronx, New York, from October 1, 2022, to October 30, 2023. Participants included either adult patients newly diagnosed (ND) with HMs or those already diagnosed, undergoing cellular therapy (CT). The severity of FT was assessed using the validated Comprehensive Score for Financial Toxicity–Functional Assessment of Chronic Illness Therapy (COST-FACIT) questionnaire. Additionally, an investigator-designed questionnaire was developed to gather sociodemographic data and evaluate the subjective effects of financial burden on patient care. Patients in both the ND and CT groups were followed for 90 days. Data collection occurred at their initial presentation, as well as on days 30 and 90. Results: Ninety patients participated in the study (ND=52 and CT=38). The median age was 59 (IQR 44-66) years, with 27% (n=24) African American and 55% (n=48) Hispanic. Overall, 75% (n=67) of participants experienced some degree of FT, most with mild FT at baseline (day 0, median COST-FACIT score=19.4). In the CT group, FT worsened significantly over time, with a decline in median COST-FACIT scores from 19.9 at day 0 to 15.5 on day 90 ( P =.02). In a multivariable linear regression model, race and ethnicity were a significant predictor of FT burden: identifying as African American or Hispanic was associated with a significantly lower COST-FACIT score (ie, higher FT) compared to non-Hispanic White participants (B=−3.08, P =.04, 95% CI −6.05 to −0.12). Additionally, over half of ND and CT participants reported difficulty affording basic necessities (ND: 28/52, 54%; CT: 23/38, 61%) and concerns regarding transportation access and costs (ND: 26/50, 52%; CT: n=18/38, 47%). Conclusions: FT is prevalent among patients with HMs receiving care in underserved populations, and the burden is significantly higher among African American and Hispanic populations.

25 November 2025
Verified
Other
Open access
DLDavid Levitz
David Levitz
YSYogen Saunthararajah
Yogen Saunthararajah
KFKateryna Fedorov
Kateryna Fedorov
LSLauren C. Shapiro
Lauren C. Shapiro
IMIoannis Mantzaris
Ioannis Mantzaris
MGMendel Goldfinger
Mendel Goldfinger
Supplementary table on representativeness

21 June 2023
Verified
Other
Open access
DLDavid Levitz
David Levitz
YSYogen Saunthararajah
Yogen Saunthararajah
KFKateryna Fedorov
Kateryna Fedorov
LSLauren C. Shapiro
Lauren C. Shapiro
IMIoannis Mantzaris
Ioannis Mantzaris
MGMendel Goldfinger
Mendel Goldfinger
Supplementary table on representativeness

1 August 2023
Verified
Other
Open access
DLDavid Levitz
David Levitz
YSYogen Saunthararajah
Yogen Saunthararajah
KFKateryna Fedorov
Kateryna Fedorov
LSLauren C. Shapiro
Lauren C. Shapiro
IMIoannis Mantzaris
Ioannis Mantzaris
MGMendel Goldfinger
Mendel Goldfinger
Supplementary table on representativeness

21 June 2023
Verified
Other
Open access
DLDavid Levitz
David Levitz
YSYogen Saunthararajah
Yogen Saunthararajah
KFKateryna Fedorov
Kateryna Fedorov
LSLauren C. Shapiro
Lauren C. Shapiro
IMIoannis Mantzaris
Ioannis Mantzaris
MGMendel Goldfinger
Mendel Goldfinger
Supplementary table on representativeness